Despite the wide adoption of statins that are practically in the U.S. drinking water, there are still Americans who are not being treated with lipid-lowering therapies. So what's the answer? Dr. James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells the Chicago Tribune's Bruce Japsen about combination therapies and other new drugs being pursued by the pharmaceutical industry to manage cholesterol.
Combination Therapy to Manage Lipids
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Despite the wide adoption of statins that are practically in the U.S. drinking water, there are still Americans who are not being treated with lipid-lowering therapies. So what's the answer? Dr. James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells the Chicago Tribune's Bruce Japsen about combination therapies and other new drugs being pursued by the pharmaceutical industry to manage cholesterol.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
<p>Navigating Myasthenia Gravis in Adolescents and Young Adults</p>
Clinician's Roundtable
Challenges in AI-Driven Dermatology: Understanding Current Limitations
<p>Challenges in AI-Driven Dermatology: Understanding Current Limitations</p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
ACC Action Center
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
<p>Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?